Skip to content

Evaluation of the human efficacy of OGP photon rejuvenation device

Evaluation of the human efficacy of OGP photon rejuvenation device

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086767
Enrollment
Unknown
Registered
2024-07-10
Start date
2023-09-04
Completion date
Unknown
Last updated
2024-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chinese healthy skin female subjects aged 25-50 were evaluated using the OGP photon rejuvenation device to evaluate the human efficacy of the product.

Interventions

Test group:OGP multi band photon skin brightener

Sponsors

The First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1: Chinese women aged 25 to 50 with healthy facial skin 2: Those with no symptoms related to skin barrier damage on the facial skin 3: Those who agree to avoid exposure to sunlight during the testing period 4: Can read Chinese and accurately understand, signed informed consent form for testing and research 5: Those who are able to use test products and cooperate with testing according to requirements, and can promptly reflect any discomfort symptoms after use.

Exclusion criteria

Exclusion criteria: 1: Pregnant or lactating women 2: Individuals with obvious sunburn, scars, pigmented nevi, hirsutism, or facial nerve disorders on the face that may affect the test results 3: Individuals with bacterial, viral, or fungal infections on their facial skin 4: Individuals with sensitive skin or chronic skin diseases (such as skin tumors, rosacea, acne, eczema, lupus erythematosus, seborrheic dermatitis, psoriasis, severe epidermal detachment, etc.) 5: Having a history of immunosuppressive or immunodeficient diseases (including HIV or AIDS), or currently using immunosuppressive drugs or radiation therapy 6: People with heart disease, asthma, epilepsy, diabetes, hypertension, high myopia (above -6D), retinal detachment or those who have suffered from retinal detachment, hemorrhagic diseases, hemophiliacs and other blood abnormalities, chronic diseases and endocrine diseases such as hyperthyroidism or hypothyroidism 7: Participate in other clinical trials or similar tests within 3 months 8: In the past 6 months or currently using any medication that may affect skin condition or reactions, such as antihistamines, antibiotics, insulin, anti-inflammatory drugs, vitamin A, steroids, aspirin, thyroid drugs, etc 9: Within 6 months, medical beauty treatments have been performed on the face, such as laser therapy, chemical exfoliation, and minimally invasive beauty treatments such as botulinum toxin 10: Individuals with a history of mental illness or inability to take care of themselves 11: Growing up children, individuals who cannot express themselves (otherwise it can easily lead to skin injury, inflammation, increased pain, or severe symptoms) 12: Individuals who have undergone metal, silicone, plastic or other implant surgeries on the face due to fractures, plastic surgery, etc 13: Individuals with head and eye sequelae due to traffic accidents or other reasons 14: People whose skin lacks sensory ability.

Design outcomes

Primary

MeasureTime frame
Facial Assessment Form;

Secondary

MeasureTime frame
Adverse events;

Countries

China

Contacts

Public ContactZhangLi

The First Affiliated Hospital of China Medical University

lizhang_1001@126.com+86 139 4002 3570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026